GlassScriptPhysician profile
Kaitlin E Schwerer
NPI 1659767812
$5,790.38
in general payments reported to CMS, 2019-2025
40 companies · $1,261 in 2025
The $1,261 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $734 · 2021: $394 · 2022: $346 · 2023: $707 · 2024: $1,444 · 2025: $1,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,431.74 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $601.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $514.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $430.48 | 2019-2025 | |
| Lilly USA, LLC | $429.71 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $225.14 | 2024-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $199.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $173.07 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $151.74 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.86 | 2020-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $133.96 | 2019-2021 | |
| Astellas Pharma US INC | $131.64 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.78 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $106.62 | 2019-2021 | |
| Corcept Therapeutics | $89.88 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Schwerer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.